Abstract 238MO
Background
Air pollution, classified as carcinogenic to humans, is a major public health concern. Studies on breast cancer are scarce and remain inconsistent. We studied the association between breast cancer risk and long-term exposure to particulate matters (PM2.5, PM10) and nitrogen dioxide (NO2) estimated at the womens' residential and workplace addresses.
Methods
We conducted a case-control study of 2419 cases and 2984 individually matched controls nested in the French prospective E3N cohort, over the period 1990-2011. Controls were matched to cases on department of residence, age (±1 year); date (±3 months), and menopausal status at blood collection. Annual mean PM2.5, PM10 and NO2 concentration levels were estimated using a Land Use Regression (LUR) model (resolution 50m x 50m) and were assigned to women based on their geocoded residential and workplace addresses. The mean exposure was calculated for each woman from their inclusion into the E3N cohort to their index date (date of diagnosis of cases). Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariate logistic regression models, for a 10 μg/m3 increase in PM2.5, PM10 and NO2. Adjustment variables were selected from the literature, using a directed acyclic graph.
Results
The results showed a statistically significant linear increase in breast cancer risk related to mean exposure to PM2.5 (adjusted OR 1.28; CI 1.00–1.63, for an increment of 10 μg/m3). A numerically increased risk was observed for PM10 (adjusted OR1.09; CI 0.92–1.30) and NO2 (adjusted OR 1.05; CI 0.97–1.13) for an increment of 10 μg/m3. No effect modification by menopausal status was observed (p interaction 0.99, 0.90, and 0.86 respectively for PM2.5PM10 and NO2). Analyses by hormone receptor status showed a positive but not significant association for PM2.5 for oestrogen receptor positive (ER+) breast cancer cases (adjusted OR 1.32; CI 0.97–1.79).
Conclusions
To our knowledge, this study is the first to investigate breast cancer risk associated with long term air pollution exposure at both, the subjects’ residence and workplace, estimated using a very fine spatial resolution LUR model. Future studies should consider exposure during commuting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
INSERM.
Funding
ARC Foundation for Cancer Research (CANCAIR201601245), ANSES, French League against Cancer, Fondation de France.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
LBA22 - Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: Results from the DISCO randomized trial
Presenter: Beatrice Fervers
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
239MO - Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials
Presenter: Haizhu Chen
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant 238MO, LBA22 and 239MO
Presenter: Ines Vaz Luis
Session: Mini oral session - Breast cancer, early stage
Resources:
Slides
Webcast
240MO - Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)
Presenter: Matthew Goetz
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA23 - Invasive disease–free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)
Presenter: Aditya Bardia
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
241MO - Patient characteristics and real-world outcomes in HER2 negative/ ER zero and ER low patients treated as triple-negative breast cancer in Sweden 2008-2020
Presenter: Irma Fredriksson
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
242MO - Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studies
Presenter: Federica Miglietta
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA24 - Multiparametric prognostic score in early HR+/HER2- breast cancer: Impact of recurrence score, clinical-pathological factors, gene mutations and histology
Presenter: Oleg Gluz
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant 240MO, LBA23, 241MO, 242MO and LBA24
Presenter: Carsten Denkert
Session: Mini oral session - Breast cancer, early stage
Resources:
Slides
Webcast
243MO - Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial
Presenter: Henry M. Kuerer
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast